DOCSLIB.ORG

2018 at a Glance: Recently Approved Therapies in Oncology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Hematology & Oncology 2018 at a glance: Recently approved therapies in oncology BY EMILY BRYER, DO; DAVID MINTZER, MD; Dose: 240 mg orally, once daily. Dacomitinib (Vizimpro) AND DAVID HENRY, MD Adverse Events (AEs): Hyperkalemia and increased Class: Second-generation tyrosine kinase inhibitor. risks of seizures, falls, and fractures. Disease: Metastatic non–small cell lung cancer dvances in genomics and technology per- Phase 3 SPARTAN trial (NCT01946204): 40.5-month (NSCLC) with epidermal growth factor receptor petually change and improve therapies in metastasis-free survival rate, compared with 16.2 (EGFR) exon 19 deletion or exon 21 L858R substi- oncology. Enhanced comprehension of cel- months in the placebo group. tution mutation. lular signaling, division, and replication has Dose: 45 mg orally once daily. createdA a platform to selectively restrict neoplastic Cemiplimab (Libtayo) AEs: Dermatotoxicity and diarrhea. growth while preserving the integrity of benign Class: Antibody against programmed cell death ARCHER1050 trial (NCT01774721): Patients who cells. protein-1 (PD-1). received dacomitinib demonstrated an improved This article reviews therapies that were newly Disease: Metastatic cutaneous squamous cell car- overall survival, with a median of 34.1 months, approved in 2018, as well as those previously ap- cinoma (CSCC) or locally advanced CSCC that is compared with 26.8 months with gefitinib. proved whose indications were expanded this past ineligible for curative surgery/radiation. year. The list highlights the most clinically import- Dose: 350 mg intravenous infusion every 3 weeks. Duvelisib (Copiktra) ant approvals, as well as adverse events that are AEs: Pneumonitis, autoimmune myocarditis, hepa- Class: Dual inhibitor of phosphatidylinositol 3-ki- unique or especially severe. titis, and aseptic meningitis. nase delta and gamma. 1423 and 1540 trials (NCT02383212 and Disease: Relapsed or refractory chronic lymphocyt- Apalutamide (Erleada) NCT02760498): 47.2% of patients who received ic leukemia (CLL), small lymphocytic lymphoma, Class: Androgen receptor inhibitor. cemiplimab had complete disappearance of the tu- or relapsed or refractory follicular lymphoma after Disease: Nonmetastatic castration-resistant pros- mor or a decrease in tumor size. at least two prior systemic therapies. 139308a tate cancer. Dose: 25 mg orally twice daily. Expanded indications for previously approved drugs Drug name Previous indication New indication Landmark study Olaparib (Lynparza) • Maintenance recurrent ovarian cancer • First-line maintenance for BRCA-mutated advanced epithelial SOLO-1 • Advanced germline BRCA mutated ovarian cancer ovarian, fallopian tube, or primary peritoneal cancer (NCT01844986) Pembrolizumab • Unresectable or metastatic melanoma • Recurrent locally advanced or metastatic Merkel cell carcinoma KEYNOTE-017 (Keytruda) • Unresectable or metastatic solid tumors that are microsatellite • Hepatocellular carcinoma in patients who received sorafenib (NCT02267603) instability–high or mismatch repair decient • First-line treatment in combination with chemotherapy for KEYNOTE-224 • Metastatic NSCLC with high program death-ligand 1 expression metastatic squamous NSCLC (NCT02702414) IMNG Print Colors Headline for a Bar Graphic • Recurrent or metastatic NSCLC KEYNOTE-407 If a deck headline is needed, use this style. • Classical Hodgkin lymphoma (NCT02775435) • Recurrent or metastatic cervical cancer Label style and size Nivolumab (Opdivo) • Metastatic melanoma • Metastatic small-cell lung cancer with progression after CHECKMATE-032 • Metastatic NSCLC platinum-based therapy and an additional therapy (NCT01928394) Axes number style and size • Renal cell carcinoma Note: Trade Gothic Medium, 8/11 ush left • Hodgkin lymphoma • Recurrent or metastatic head and neck squamous cell carcinoma Source: Trade Gothic Medium, 8/11 ush left • Locally advanced or metastatic urothelial carcinoma • Microsatellite instability–high or mismatch repair decient Style Guide: metastatic colorectal cancer Keep the background white. • Hepatocellular carcinoma Use the IMNG colors. Brentuximab vedotin • Cutaneous anaplastic large cell lymphoma • Previously untreated systemic anaplastic large-cell lymphoma ECHELON-2 Move the entire graph to align the bar labels left at the blue guide bar. (Acetris) combined • CD30-expressing mycosis fungoides or other CD30-expressing peripheral T-cell lymphomas (NCT01777152) (Resizing may need to be done on the graph to t in the space.) with chemotherapy • Classical Hodgkin lymphoma at high risk of relapse or progression after auto-HSCT consolidation If a deeper or shorter template is needed, adjust in Window > Artboards. • Classical Hodgkin lymphoma after failure of auto-HSCT or after (Standard, as shown here, is 28 picas x 20 picas.) failure of at least two prior multiagent therapies To create the dotted lines if they change, use the clear arrow tool, click Dabrafenib (Tanlar) • Metastatic NSCLC with BRAF 600E mutation • Unresectable or metastatic BRAF V600E mutation–positive BRF117019 on the line that needs to be changed, use the eyedropper tool, then combined with anaplastic thyroid cancer (NCT02034110) click on the dotted rule provided on the side of the template. Trametinib (Mekinist) • Melanoma with BRAF V600E or V600K mutations COMBI-AD (NCT01682083) Blinatumomab • Relapsed or refractory Philadelphia chromosome–negative • B-cell precursor acute lymphoblastic leukemia who are in BLAST (Blincyto) B-cell precursor acute lymphoblastic leukemia remission but still have minimal residual disease (NCT01207388) • Relapsed or refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia MDedge News Note: NSCLC = non–small cell lung cancer, HSCT = hematopoietic stem cell transplantation, BRAF = v-raf murine sarcoma viral oncogene homolog B1. Source: Dr. Bryer, Dr. Mintzer, and Dr. Henry MDedge.com/hematology-oncology ■ April 2019 Hematology & Oncology 139308b AEs: Infection, diarrhea or colitis, and pneumonia. 2018 biosimilars Phase 3 DUO trial (NCT02004522): Progression-free survival in the duvelisib arm was 7.3 months lon- Name Biosimilar to: Indication Headline for a Bar Graphic ger than that in the ofatumumab arm. The overall IMNG Print Colors Adalimumab-adaz Adalimumab • Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, If a deck headline is needed, use this style. response rate for patients receiving duvelisib was (Hyrimoz) ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, plaque psoriasis 78%, compared with 39% for those receiving ofa- Epoetin alfa-epbx Epoetin alfa • Anemia related to chronic kidney disease, zidovudine with HIV infection, Label style and size tumumab. (Retacrit) myelosuppressive chemotherapy • Reduction of allogenic red blood cell transfusions in elective and noncardiac/ Axes number style and size Gilteritinib (Xospata) nonvascular surgery Note: Trade Gothic Medium, 8/11 ush left Class: Inhibits the FLT3 internal tandem dupli- Filgrastim-aa Filgrastim • Decrease incidence of infection in patients receiving myelosuppressive cation (ITD) and FLT3 tyrosine kinase domain (Nivestym) chemotherapy Source: Trade Gothic Medium, 8/11 ush left (TKD). • Reduce the time to neutrophil recovery and duration of fever in patients with acute myeloid leukemia Style Guide: Disease: Relapsed or refractory acute myeloid leu- • Mobilize autologous hematopoietic progenitor cells into the peripheral blood Keep the background white. kemia (AML) with an FLT3 mutation. for collection by leukapheresis Dose: 120 mg orally daily. Use the IMNG colors. Peglgrastim-jmdb Peglgrastim • Decrease the incidence of infection in patients with nonmyeloid malignancies Move the entire graph to align the bar labels left at the blue guide bar. ADMIRAL trial (NCT02421939): 21% of the patients (Fulphila) receiving myelosuppressive anticancer drugs associated with a signicant (Resizing may need to be done on the graph to t in the space.) who received gilteritinib exhibited complete remis- incidence of febrile neutropenia If a deeper or shorter template is needed, adjust in Window > Artboards. sion or complete remission with partial hemato- Peglgrastim-cbqv Peglgrastim • Same indications as peglgrastim-jmdb logic recovery. (Udenyca) (Standard, as shown here, is 28 picas x 20 picas.) Rituximab-abbs Rituximab • CD20-positive B-cell non-Hodgkin lymphoma To create the dotted lines if they change, use the clear arrow tool, click Glasdegib (Daurismo) (Trumixa) on the line that needs to be changed, use the eyedropper tool, then Class: Hedgehog pathway inhibitor. Trastuzumab-pkrb Trastuzumab • HER2-overexpressing breast cancer click on the dotted rule provided on the side of the template. Disease: Adults over age 75 years with newly diag- (Herzuma) nosed AML and other medical comorbidities that MDedge News preclude them from intensive chemotherapy. Source: Dr. Bryer, Dr. Mintzer, and Dr. Henry Dose: The recommended dose is 100 mg orally continuously in 28-day cycles. AE: QT prolongation and embryo-fetal toxicity Larotrectinib (Vitrakvi) Moxetumomab pasudotox-tdfk (Lumoxiti) Phase 2 BRIGHT 1003 trial (NCT01546038): Class: Oral tyrosine kinase inhibitor. Class: CD22-directed cytotoxin fused with a frag- 3.9-month overall survival advantage for glasdegib Disease: Advanced solid tumors harboring a neu- ment of Pseudomonas exotoxin A. plus cytarabine, compared with cytarabine alone. rotrophic tyrosine receptor kinase (NTRK) gene Disease: Relapsed or refractory hairy cell leukemia Overall,
Recommended publications
  • Moxetumomab Pasudotox-Tdfk

    Moxetumomab Pasudotox-Tdfk

    Wednesday, March 11, 2020 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Michyla Adams, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – March 11, 2020 DATE: February 24, 2020 NOTE: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the March meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – Appendix B Action Item – Vote to Prior Authorize Xcopri® (Cenobamate) – Appendix C Action Item – Vote to Prior Authorize Tosymra™ (Sumatriptan Nasal Spray), Reyvow™ (Lasmiditan), and Ubrelvy™ (Ubrogepant) – Appendix D Action Item – Vote to Prior Authorize Esperoct® [Antihemophilic Factor (Recombinant), Glycopegylated-exei] – Appendix E Action Item – Vote to Prior Authorize ProAir® Digihaler™ (Albuterol Sulfate Inhalation Powder) – Appendix F Action Item – Vote to Prior Authorize Evenity® (Romosozumab-aqqg) – Appendix G Action Item – Vote to Prior Authorize Asparlas™ (Calaspargase Pegol-mknl), Daurismo™ (Glasdegib), Idhifa® (Enasidenib), Lumoxiti® (Moxetumomab Pasudotox-tdfk), Tibsovo® (Ivosidenib), and Xospata® (Gilteritinib) – Appendix H Action Item – Vote to Prior Authorize Azedra® (Iobenguane I-131) – Appendix I Annual Review of Lymphoma Medications and 30-Day Notice to Prior Authorize Aliqopa™ (Copanlisib), Brukinsa™ (Zanubrutinib), Polivy™ (Polatuzumab Vedotin-piiq), and Ruxience™ (Rituximab-pvvr) – Appendix J Annual Review of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib) – Appendix K Annual Review of Multiple Sclerosis (MS) Medications and 30-Day Notice to Prior Authorize Mayzent® (Siponimod), Mavenclad® (Cladribine), and Vumerity™ (Diroximel Fumarate) – Appendix L ORI-4403 • P.O.
  • Mekinist, INN-Trametinib

    Mekinist, INN-Trametinib

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Mekinist 0.5 mg film-coated tablets Mekinist 2 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Mekinist 0.5 mg film-coated tablets Each film-coated tablet contains trametinib dimethyl sulfoxide equivalent to 0.5 mg of trametinib. Mekinist 2 mg film-coated tablets Each film-coated tablet contains trametinib dimethyl sulfoxide equivalent to 2 mg of trametinib. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Mekinist 0.5 mg film-coated tablets Yellow, modified oval, biconvex, film-coated tablets, approximately 4.8 x 8.9 mm, with “GS” debossed on one face and “TFC” on the opposing face. Mekinist 2 mg film-coated tablets Pink, round, biconvex, film-coated tablets, approximately 7.5 mm, with “GS” debossed on one face and “HMJ” on the opposing face. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1). 4.2 Posology and method of administration Treatment with trametinib should only be initiated and supervised by a physician experienced in the administration of anti-cancer medicinal products.
  • Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (Enrollment Anticipated in 2018) Eligibility: • at Least 2 Prior Treatments, Including Purine Analog

    Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (Enrollment Anticipated in 2018) Eligibility: • at Least 2 Prior Treatments, Including Purine Analog

    Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (enrollment anticipated in 2018) Eligibility: • At least 2 prior treatments, including purine analog. • Need for treatment (low blood counts or spleen pain) • No prior recombinant toxin • Hairy cell leukemia variant (HCLv) accepted Rationale • Moxetumomab pasudotox, formally called HA22 or CAT-8015, is a recombinant immunotoxin made out of 2 parts, an antibody part binding to CD22 on B-cells, and a toxin part (domain II and III) which kills the cell. • The toxin is extremely potent, only 1 molecule in the cytoplasm is enough to kill a cell. • HCL cells have much more CD22 than normal B-cells. • Normal B-cells rapidly regenerate from CD22-negative cells, but HCL cells may not return if eradicated. • ~50% complete remission (CR) rate at the highest dose level. (https://www.ncbi.nlm.nih.gov/pubmed/22355053). • Most of these complete remissions (CRs) had no minimal residual disease (MRD) and did not relapse. • Although severe toxicity was not seen, a low-grade hemolytic uremic syndrome, with temporary decrease in platelets and increase in creatinine, was seen in 2 of 49 patients. Design • 30 minute iv infusion every other day for 3 doses, repeat every 4 weeks for 6 cycles. • Patients are then followed without treatment. Cladribine With Simultaneous or Delayed Rituximab for early HCL Cladribine (daily x5) Rituximab weekly x8 (CDAR) |||||||| |||||||| Cladribine + immediate Rituximab vs > 6 mo |||||||| Cladribine + delayed Rituximab |||||||| • Eligibility: 0-1 prior purine analog, or HCL variant (HCLv), and need for treatment (i.e. low blood counts) • Minimal residual disease (MRD) after purine analog (cladribine or pentostatin) may cause relapse.
  • Center for Drug Evaluation and Research

    Center for Drug Evaluation and Research

    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 125554Origs051 Trade Name: OPDIVO Generic or Proper nivolumab Name: Sponsor: Bristol-Myers Squibb Company Approval Date: March 05, 2018 Indication: Opdivo is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of: • patients with BRAF V600 wild-type unresectable or metastatic melanoma, as a single agent. (1.1) • patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, as a single agent.a (1.1) • patients with unresectable or metastatic melanoma, in combination with ipilimumab.a (1.1) • patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. (1.2) • patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFT or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.3) • patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.4) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed afterb: (1.5) o autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or o 3 or more lines of systemic therapy that includes autologous HSCT. • patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy (1.6) • patients with locally advanced or metastatic urothelial carcinoma whob: o have disease progression during or following platinum-containing chemotherapy o have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum- containing chemotherapy.
  • Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma

    Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma

    Review Melanoma Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma Antonio M Grimaldi, Ester Simeone, Lucia Festino, Vito Vanella and Paolo A Ascierto Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy cquired resistance is the most common cause of BRAF inhibitor monotherapy treatment failure, with the majority of patients experiencing disease progression with a median progression-free survival of 6-8 months. As such, there has been considerable A focus on combined therapy with dual BRAF and MEK inhibition as a means to improve outcomes compared with monotherapy. In the COMBI-d and COMBI-v trials, combined dabrafenib and trametinib was associated with significant improvements in outcomes compared with dabrafenib or vemurafenib monotherapy, in patients with BRAF-mutant metastatic melanoma. The combination of vemurafenib and cobimetinib has also been investigated. In the phase III CoBRIM study in patients with unresectable stage III-IV BRAF-mutant melanoma, treatment with vemurafenib and cobimetinib resulted in significantly longer progression-free survival and overall survival (OS) compared with vemurafenib alone. One-year OS was 74.5% in the vemurafenib and cobimetinib group and 63.8% in the vemurafenib group, while 2-year OS rates were 48.3% and 38.0%, respectively. The combination was also well tolerated, with a lower incidence of cutaneous squamous-cell carcinoma and keratoacanthoma compared with monotherapy. Dual inhibition of both MEK and BRAF appears to provide a more potent and durable anti-tumour effect than BRAF monotherapy, helping to prevent acquired resistance as well as decreasing adverse events related to BRAF inhibitor-induced activation of the MAPK-pathway.
  • Mekinist, INN-Trametinib

    Mekinist, INN-Trametinib

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Mekinist 0.5 mg film-coated tablets Mekinist 2 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Mekinist 0.5 mg film-coated tablets Each film-coated tablet contains trametinib dimethyl sulfoxide equivalent to 0.5 mg of trametinib. Mekinist 2 mg film-coated tablets Each film-coated tablet contains trametinib dimethyl sulfoxide equivalent to 2 mg of trametinib. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Mekinist 0.5 mg film-coated tablets Yellow, modified oval, biconvex, film-coated tablets, approximately 4.8 x 8.9 mm, with “GS” debossed on one face and “TFC” on the opposing face. Mekinist 2 mg film-coated tablets Pink, round, biconvex, film-coated tablets, approximately 7.5 mm, with “GS” debossed on one face and “HMJ” on the opposing face. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Melanoma Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1). Non-small cell lung cancer (NSCLC) Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
  • Tafinlar, INN-Dabrafenib

    Tafinlar, INN-Dabrafenib

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tafinlar 50 mg hard capsules Tafinlar 75 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tafinlar 50 mg hard capsules Each hard capsule contains dabrafenib mesilate equivalent to 50 mg of dabrafenib. Tafinlar 75 mg hard capsules Each hard capsule contains dabrafenib mesilate equivalent to 75 mg of dabrafenib. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule (capsule). Tafinlar 50 mg hard capsules Opaque dark red capsules, approximately 18 mm long, with capsule shell imprinted with “GS TEW” and “50 mg”. Tafinlar 75 mg hard capsules Opaque dark pink capsules, approximately 19 mm long, with capsule shell imprinted with “GS LHF” and “75 mg”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Melanoma Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Adjuvant treatment of melanoma Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. 2 4.2 Posology and method of administration Treatment with dabrafenib should be initiated and supervised by a qualified physician experienced in the use of anticancer medicinal products. Before taking dabrafenib, patients must have confirmation of tumour BRAF V600 mutation using a validated test.
  • Lumoxiti™ (Moxetumomab Pasudotox-Tdfk)

    Lumoxiti™ (Moxetumomab Pasudotox-Tdfk)

    Lumoxiti™ (moxetumomab pasudotox-tdfk) (Intravenous) -E- Document Number: IC-0474 Last Review Date: 12/01/2020 Date of Origin: 07/01/2019 Dates Reviewed: 07/2019, 12/2019, 12/2020 I. Length of Authorization Coverage is provided for six months (6 cycles) and may not be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: − Lumoxiti 1 mg SDV: 15 vials per 28 day cycle B. Max Units (per dose and over time) [HCPCS Unit]: • 500 billable units on days 1, 3 and 5 of a 28-day cycle III. Initial Approval Criteria 1-3 Coverage is provided in the following conditions: • Patient is at least 18 years or older; AND • Patient does not have severe renal impairment defined as CrCl ≤ 29 mL/min; AND • Patient does not have prior history of severe thrombotic microangiopathy (TMA) or hemolytic uremic syndrome (HUS); AND • Must be used as a single agent; AND Hairy Cell Leukemia (HCL) † Ф 1-4 • Patient has a confirmed diagnosis of Hairy Cell Leukemia or a HCL variant; AND • Patient must have relapsed or refractory disease; AND • Patient has previously failed at least TWO prior systemic therapies consisting of one of the following: o Failure to two courses of purine analog therapy (e.g., cladribine, pentostatin, etc.); OR o Failure to at least one purine analog therapy AND one course of rituximab or a BRAF- inhibitor (e.g., vemurafenib, etc.) Moda Health Plan, Inc. Medical Necessity Criteria Page 1/6 Preferred therapies and recommendations are determined by review of clinical evidence. NCCN category of recommendation is taken into account as a component of this review.
  • MEK Inhibition Is a Promising Therapeutic Strategy for MLL-Rearranged Infant Acute Lymphoblastic Leukemia Patients Carrying RAS Mutations

    MEK Inhibition Is a Promising Therapeutic Strategy for MLL-Rearranged Infant Acute Lymphoblastic Leukemia Patients Carrying RAS Mutations

    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 9), pp: 14835-14846 Research Paper MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations Mark Kerstjens1,*, Emma M.C. Driessen1,*, Merel Willekes1, Sandra S. Pinhanços1, Pauline Schneider1, Rob Pieters1,2, Ronald W. Stam1 1Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands 2Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands *These authors have contributed equally to this work Correspondence to: Ronald W. Stam, email: [email protected] Keywords: MLL-rearrangements, RAS-pathway, leukemia, MEK inhibitors Received: May 31, 2016 Accepted: August 13, 2016 Published: August 31, 2016 ABSTRACT Acute lymphoblastic leukemia (ALL) in infants is an aggressive malignancy with a poor clinical outcome, and is characterized by translocations of the Mixed Lineage Leukemia (MLL) gene. Previously, we identified RAS mutations in 14-24% of infant ALL patients, and showed that the presence of a RAS mutation decreased the survival chances even further. We hypothesized that targeting the RAS signaling pathway could be a therapeutic strategy for RAS-mutant infant ALL patients. Here we show that the MEK inhibitors Trametinib, Selumetinib and MEK162 severely impair primary RAS-mutant MLL-rearranged infant ALL cells in vitro. While all RAS-mutant samples were sensitive to MEK inhibitors, we found both sensitive and resistant samples among RAS-wildtype cases. We confirmed enhanced RAS pathway signaling in RAS- mutant samples, but found no apparent downstream over-activation in the wildtype samples. However, we did confirm that MEK inhibitors reduced p-ERK levels, and induced apoptosis in the RAS-mutant MLL-rearranged ALL cells.
  • Overcoming Resistance to BRAFV600E Inhibition in Melanoma by Deciphering and Targeting Personalized Protein Network Alterations

    Overcoming Resistance to BRAFV600E Inhibition in Melanoma by Deciphering and Targeting Personalized Protein Network Alterations

    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.03.366245; this version posted November 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Overcoming Resistance to BRAFV600E Inhibition in Melanoma by Deciphering and 2 Targeting Personalized Protein Network Alterations 3 S. Vasudevan#, E. Flashner-Abramson#, I. Adesoji Adejumobi, D. Vilencki, S. Stefansky, A.M. 4 Rubinstein and N. Kravchenko-Balasha* 5 Department for Bio-medical Research, Faculty of Dental Medicine, Hebrew University of Jerusalem, 6 Jerusalem 91120, Israel 7 *Corresponding author: [email protected] 8 # Equal contribution 9 Keywords 10 Melanoma; information theory; surprisal analysis; patient-specific altered signaling signatures; 11 personalized therapy; BRAFV600E-mutated melanoma 12 13 Abstract 14 BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E 15 therapy, often relapse and their tumors develop drug resistance. While it is widely accepted that these 16 tumors are originally driven by the BRAFV600E mutation, they often eventually diverge and become 17 supported by various signaling networks. Therefore, patient-specific altered signaling signatures should be 18 deciphered and treated individually. 19 In this study, we design individualized melanoma combination treatments based on personalized network 20 alterations. Using an information-theoretic approach, we compute high-resolution patient-specific altered 21 signaling signatures. These altered signaling signatures each consist of several co-expressed subnetworks, 22 which should all be targeted to optimally inhibit the entire altered signaling flux. Based on these data, we 23 design smart, personalized drug combinations, often consisting of FDA-approved drugs.
  • FOI Reference: FOI 414 - 2021

    FOI Reference: FOI 414 - 2021

    FOI Reference: FOI 414 - 2021 Title: Researching the Incidence and Treatment of Melanoma and Breast Cancer Date: February 2021 FOI Category: Pharmacy FOI Request: 1. How many patients are currently (in the past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+? 2. In the past 3 months, how many melanoma patients (any stage) were treated with the following: • Cobimetinib • Dabrafenib • Dabrafenib AND Trametinib • Encorafenib AND Binimetinib • Ipilimumab • Ipilimumab AND Nivolumab • Nivolumab • Pembrolizumab • Trametinib • Vemurafenib • Vemurafenib AND Cobimetinib • Other active systemic anti-cancer therapy • Palliative care only 3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY: • Ipilimumab • Ipilimumab AND Nivolumab • Nivolumab • Pembrolizumab • Any other therapies 4. In the past 3 months how many patients were treated with the following for breast cancer? • Abemaciclib + Anastrozole/Exemestane/Letrozole • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Atezolizumab • Bevacizumab [Type text] • Eribulin • Everolimus + Exemestane • Fulvestrant as a single agent • Gemcitabine + Paclitaxel • Lapatinib • Neratinib • Olaparib • Palbociclib + Anastrozole/Exemestane/Letrozole • Palbociclib + Fulvestrant • Pertuzumab + Trastuzumab + Docetaxel • Ribociclib + Anastrozole/Exemestane/Letrozole • Ribociclib + Fulvestrant • Talazoparib • Transtuzumab + Paclitaxel • Transtuzumab as a single agent • Trastuzumab emtansine • Any other
  • Oncology Drug Shortage Update

    Oncology Drug Shortage Update

    ] ] [ News ] Analysis ] Commentary ] Controversy ] June 25, 2013 Vol. 35 No. 12 oncology-times.com ONCOLOGY e 5 Y ars 3 of g P in u t b a l r i s b h e i l n e g IMES C 35 TThe Independent Hem/Onc News Source Oncology Drug Shortage Update BY HEATHER LINDSEY new survey documents that cancer drug shortages have occurred A frequently, led to treatment delays, increased the risks of errors and adverse outcomes, complicated research, and increased the costs of medications� The survey, by the Hematology-Oncology Pharmacy Association, is the first to focus specifically on oncology� Page 14 • Advanced NSCLC: 60 Gy Standard • Seminoma: Opting Out of Adjuvant Therapy Safe LUNG CANCER: • Immunotherapy ‘Poised to Change Treatment Paradigm’ Leukemia Researcher Lukas Meeting Spotlights • DLBCL: CT Surveillance Adds Little Value Wartman Describes 10-Year Progress in Molecularly • CLL: Enthusiasm for Idelalisb Personal Battle Against Guided Therapy p.10 • Fitness & Cancer Prognosis pp.18, 25, 28, 33, 36, 37 Adult ALL p.20 [ALSO] SHOP TALK �� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �3 EDITH PEREZ: How I Treat Patients with Advanced HER2-Positive Breast Cancer � � � � � � � � � � �5 Exercise, Estrogen, & Breast Cancer Risk: New Data �� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �11 JOE SIMONE: Changing Views of Leaders and Leadership � � � � � � � � � � � � � � � � � � � � � � � � � � � � �16 Science Symposium for ACS’s 100th Anniversary �� � � � � � � � � � � � � � � � � � � � � � � �